Jonathan C. Fox

2.0k total citations · 1 hit paper
22 papers, 938 citations indexed

About

Jonathan C. Fox is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan C. Fox has authored 22 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 5 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan C. Fox's work include Amyloidosis: Diagnosis, Treatment, Outcomes (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers). Jonathan C. Fox is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers). Jonathan C. Fox collaborates with scholars based in United States, Italy and United Kingdom. Jonathan C. Fox's co-authors include Daniel Jacoby, Franco Cecchi, James Signorovitch, Eric M. Green, Iacopo Olivotto, Neal K. Lakdawala, James S. Ware, Allison L. Cirino, Alexandre C. Pereira and Carolyn Y. Ho and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Jonathan C. Fox

20 papers receiving 916 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

2018 456 citations Carolyn Y. Ho, Sharlene M. Day et al. Circulation profile →

Peers

Countries citing papers authored by Jonathan C. Fox

Since Specialization

Citations

This map shows the geographic impact of Jonathan C. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan C. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan C. Fox more than expected).

Fields of papers citing papers by Jonathan C. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan C. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan C. Fox. The network helps show where Jonathan C. Fox may publish in the future.

Co-authorship network of co-authors of Jonathan C. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan C. Fox. A scholar is included among the top collaborators of Jonathan C. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan C. Fox. Jonathan C. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy 2025 ·Journal of the American College of Cardiology ·Daniel P. Judge, Kevin Alexander, Francesco Cappelli, (unknown), Pablo García‐Pavía, Simon Gibbs, Martha Grogan, Mazen Hanna, Ahmad Masri, Mathew S. Maurer, Laura Obici, Prem Soman, Xiaofan Cao, Ted Lystig, Jean‐François Tamby, Suresh Siddhanti, Adam Castaño, Leonid Katz, Jonathan C. Fox, (unknown), Julian D. Gillmore	7
2	ACORAMIDIS IMPROVES SERUM TTR LEVELS IN PATIENTS WITH WILD-TYPE OR VARIANT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY 2025 ·Journal of the American College of Cardiology ·Margot K. Davis, Kevin Alexander, Amrut V. Ambardekar, Daniel P. Judge, (unknown), (unknown), Michel G. Khouri, Richard K. Cheng, Richard F. Wright, Robert Gordon, (unknown), Suresh Siddhanti, (unknown), Jonathan C. Fox, Alan X. Ji, Uma Sinha, Julian D. Gillmore, Mathew S. Maurer	0
3	PRIMARY ENDPOINT EFFICACY RESULTS IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED SENSITIVITY ANALYSES ADDRESSED TAFAMIDIS USE 2025 ·Journal of the American College of Cardiology ·Daniel P. Judge, Laura Obici, Sumeet S. Mitter, James E. Hoffman, Kunal Bhatt, Jan M. Griffin, Steen Hvitfeldt Poulsen, (unknown), Suresh Siddhanti, (unknown), Adam Castaño, Uma Sinha, Jonathan C. Fox, Francesco Cappelli	0
4	Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review 2021 ·Canadian Journal of Cardiology ·Khalil Anchouche, Malik Elharram, (unknown), (unknown), Robert Avram, Guillaume Marquis‐Gravel, Varinder K. Randhawa, Richard Nkulikiyinka, Wei Ni, Mona Fiuzat, Christopher M. O’Connor, Mitchell A. Psotka, Jonathan C. Fox, Benoît Tyl, David Kao, Abhinav Sharma	20
5	Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups 2021 ·Orphanet Journal of Rare Diseases ·David Rintell, (unknown), (unknown), Elizabeth Cross, Theodore P. Cross, (unknown), Bruno Gagnon, Cameron J. Turtle, Alan S. Cohen, (unknown), Jonathan C. Fox	22
6	Abstract 14214: ATTRibute-CM: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Phase 3 Study of AG10 in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) 2019 ·Circulation ·Julian D. Gillmore, Pablo García‐Pavía, Martha Grogan, Mazen Hanna, Stephen B. Heitner, Daniel Jacoby, Mathew S. Maurer, Claudio Rapezzi, Sanjiv J. Shah, Jitendra Ganju, Leonid Katz, Jonathan C. Fox, Daniel P. Judge	5
7	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy 2019 ·Journal of the American College of Cardiology ·Daniel P. Judge, Stephen B. Heitner, Rodney H. Falk, Matthew J. Maurer, Sanjiv J. Shah, Ronald Witteles, Martha Grogan, Van Selby, Daniel Jacoby, Mazen Hanna, José Nativi-Nicolau, J. Patel, (unknown), Uma Sinha, (unknown), Jonathan C. Fox	180
8	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis 2019 ·Journal of Cardiac Failure ·(unknown), (unknown), Roberta Mussinelli, Deepa M. Gopal, John L. Berk, Lawreen H. Connors, Nirupama Vellanki, Jennifer Hellawell, Omar K. Siddiqi, Jonathan C. Fox, Matthew J. Maurer, Frederick L. Ruberg	77
9	AG10 CONSISTENTLY STABILIZES TRANSTHYRETIN TO A HIGH LEVEL IN BOTH WILD TYPE AND MUTANT AMYLOID CARDIOMYOPATHY: RESPONDER ANALYSES FROM A PHASE 2 CLINICAL TRIAL 2019 ·Journal of the American College of Cardiology ·Jonathan C. Fox, Stephen B. Heitner, Rodney H. Falk, Martha Grogan, Daniel Jacoby, Daniel P. Judge, Mathew S. Maurer, Van Selby, Sanjiv J. Shah, Ronald Witteles, (unknown), Uma Sinha	2
10	First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers 2019 ·Clinical Pharmacology in Drug Development ·Jonathan C. Fox, Jennifer Hellawell, (unknown), Terry O’Reilly, Rick Lumpkin, Jesper A. Jernelius, Daniel D. Gretler, Uma Sinha	41
11	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy breakdown → 2018 ·Circulation ·Carolyn Y. Ho, Sharlene M. Day, Euan A. Ashley, Michelle Michels, Alexandre C. Pereira, Daniel Jacoby, Allison L. Cirino, Jonathan C. Fox, Neal K. Lakdawala, James S. Ware, Colleen Caleshu, Adam Helms, Steven D. Colan, Francesca Girolami, Franco Cecchi, Christine E. Seidman, Gautam Sajeev, James Signorovitch, Eric M. Green, Iacopo Olivotto, (unknown)	456
12	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis 2018 ·Journal of Medicinal Chemistry ·Mark R. Miller, Arindom Pal, (unknown), Hyun Joo, (unknown), (unknown), Dengpan Liang, (unknown), Fang Liu, (unknown), (unknown), (unknown), William K. Chan, Isabella A. Graef, Robert Zamboni, (unknown), Jonathan C. Fox, Uma Sinha, Mamoun M. Alhamadsheh	66
13	Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference 2017 ·Cardiovascular Drugs and Therapy ·Thomas J. Povsic, Robert C. Scott, Kenneth W. Mahaffey, Robert O. Blaustein, Jay M. Edelberg, Martin Lefkowitz, Scott D. Solomon, Jonathan C. Fox, Kevin E. Healy, Aarif Y. Khakoo, Douglas W. Losordo, Fady I. Malik, Brett P. Monia, Rusty L. Montgomery, Jeffrey S. Riesmeyer, Gregory G. Schwartz, Steven L. Zelenkofske, Joseph C. Wu, Scott M. Wasserman, Matthew T. Roe	8
14	Abstract 19616: AG10 Stabilizes Pathogenic TTR Variants With High Potency - Potential for an Effective Treatment for TTR Cardiomyopathy 2017 ·Isabella A. Graef, (unknown), Mark A. Miller, Mamoun M. Alhamadsheh, (unknown), Michaela Liedtke, Uma Sinha, Robert Zamboni, (unknown), Jonathan C. Fox, Daniel P. Judge	1
15	Abstract 17426: AG10 Potently and Selectively Stabilizes Transthyretin in vitro and Upon Oral Dosing in Dogs: Potential for Treating Transthyretin Amyloidosis 2017 ·Uma Sinha, (unknown), Jonathan C. Fox, Robert Zamboni, (unknown), Isabella A. Graef, Mamoun M. Alhamadsheh	1
16	Effects Of Low Dose Inhaled Theophylline (ADC4022) Co-administered With Budesonide On Inflammatory Markers And Lung Function In Patients With COPD 2010 ·Neil Barnes, S. Snape, Jonathan C. Fox, Mary Fitzgerald, Noel Snell, Ian Pavord, Peter Jeffery, Yusheng Qiu, Dave Singh, Adam Antczak, Ewa Niżankowska‐Mogilnicka	2
17	The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD 2009 ·Current Opinion in Pharmacology ·Jonathan C. Fox, (unknown)	13
18	Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development 2007 ·Drug Discovery Today ·(unknown), Jonathan C. Fox	24
19	Models of chronic obstructive pulmonary disease: a review of current status 2004 ·Drug Discovery Today Disease Models ·Jonathan C. Fox, Mary Fitzgerald	3
20	Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. 1997 ·Journal of Biological Chemistry ·Jonathan C. Fox, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact